|
50 |
Measuring C5a with functional bioassay Dr. Michael Schwenkert and Ali Qamar
|
|
51 |
The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement systemAgnieszka Belter1, Anna-Maria Barciszewska2, and Miroslawa Z. Naskręt-Barciszewska1
|
|
52 |
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.Pedro Miguel Coelho Medeiros1,2, Leon Cyranka1,3, Anne Rosbjerg3, Camilla Schjalm1, Peter Garred2,3, Reinhard Würzner2, and Tom Eirik Mollnes1,4,5
|
|
53 |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterizationSandra Wymann1, Marcel Mischnik3, David Leong2, Subhajit Ghosh3, Xiahui Tan2, Helen Cao2, Benjamin Kuehnemuth3, Glenn A Powers2, Partho Halder3, Mitchell J de Souza2, Hannah S James2, Vesna Tomasetig2, Holger Lind3, Paolo Rossato3, Catherine M Owczarek2, Saw Yen Ow2, Steven K Dower2, Adriana Baz Morelli2, Tony Rowe2, and Matthew P Hardy2
|
|
54 |
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood modelBeatrice Fageräng1, Corinna Lau2, Pedro Coelho Medeiros1, Karin E Mc Adam1, Camilla Schjalm1, Per Nilsson1,3, Peter Garred4, and Tom Eirik Mollnes1,2,5
|
|
55 |
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3Linnea Lindelöf1, David Eikrem1, Kristina Nilsson Ekdahl1,2, Peter Garred3, Bo Nilsson1, and Oskar Eriksson1
|
|
56 |
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseasesGerald F Cox1, Chin Meng Khoo2, Charlene Song1, and Judith Wu1
|
|
57 |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic developmentEllen Millman1, Daniel Mills2, Oksana Shkilnyk2, Dieudonne Sidi2, Michelle Elvington3, Tobin Cammett1, and Martin Schmidt3
|
|
58 |
Fragment-based drug design in the development of novel inhibitors against the initiating protease, C1r, of the classical pathway of complementDenise L Rohlik
|
|
59 |
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological TargetsElod Kortvely1, Antonello Caruso2, Jannik Vollmer3, Matthias Machacek3, and Robin Denhardt-Eriksson3
|
|
60 |
Role of pentraxin 3 and interaction with complement in immune defence against malaria Hang Zhong
|
|
61 |
Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samplesSarika Agarwal, Troy Gilliam, and Patrick Sexton
|
|
62 |
Complement implication in the acute kidney injury associated with rhabdomyolysisA Grunenwald, V Poillerat, M Revel, E Voilin, T Robe-Rybkine, I Boudhabhay, S Sacks, Florent Petitprez, L Gilardin, and LT Roumenina
|
